Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Annovis Bio, Inc. (ANVS : NYSE)
 
 • Company Description   
Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

Number of Employees: 8

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.33 Daily Weekly Monthly
20 Day Moving Average: 598,081 shares
Shares Outstanding: 19.49 (millions)
Market Capitalization: $45.40 (millions)
Beta: 1.57
52 Week High: $17.88
52 Week Low: $1.11
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.73% -14.01%
12 Week 90.98% 53.54%
Year To Date -53.68% -56.04%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
101 Lindenwood Drive Suite 225
-
Malvern,PA 19355
USA
ph: 484-875-3192
fax: -
ir@annovisbio.com http://www.annovisbio.com
 
 • General Corporate Information   
Officers
Maria Maccecchini - Chief Executive Officer and President
Michael Hoffman - Chairman of the Board and Director
Claudine Bruck - Director
Reid McCarthy - Director
Mark White - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03615A108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 19.49
Most Recent Split Date: (:1)
Beta: 1.57
Market Capitalization: $45.40 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.52 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.89
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 55.56%
vs. Previous Quarter: 25.58%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -300.56
12/31/24 - -872.99
ROA
06/30/25 - -
03/31/25 - -193.50
12/31/24 - -239.04
Current Ratio
06/30/25 - -
03/31/25 - 10.68
12/31/24 - 3.59
Quick Ratio
06/30/25 - -
03/31/25 - 10.68
12/31/24 - 3.59
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 1.23
12/31/24 - 0.67
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©